Artists take note: Oncology on Canvas accepting entries

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 4
Volume 17
Issue 4

The 2008 Oncology on Canvas: Expressions of a Cancer Journey art competition and exhibition, sponsored by Eli Lilly and Company in partnership with the National Coalition for Cancer Survivorship, is accepting entries to be received no later than June 30, 2008.

The 2008 Oncology on Canvas: Expressions of a Cancer Journey art competition and exhibition, sponsored by Eli Lilly and Company in partnership with the National Coalition for Cancer Survivorship, is accepting entries to be received no later than June 30, 2008.

The biennial competition invites people diagnosed with any type of cancer, their families, friends, caregivers, and healthcare providers to express, through art and narrative, the life-affirming changes that give their cancer journey meaning.

Entries can be from any of six different art media: oil, watercolor, acrylic, photography, pastel, and mixed media (any other type of one-dimensional art). Submitted artwork must be at least 12″ × 12″ and no larger than 17″ × 26″.

Artists can enter via three categories: person diagnosed with cancer; healthcare professional, eg, doctor, nurse, pharmacist, lab technician; and family member, friend, or caregiver.

An independent panel of judges will select three top prize winners who will be awarded prize money to be donated directly to a cancer charity of their choice: 1st prize $10,000, 2nd prize $5,000, and 3rd prize $2,500. Additional winners will be selected from each medium and participant category with awards of $1,000.

The 2006 1st prize US winner, for example, donated her winnings to the University of North Carolina Lineberger Comprehensive Cancer Center, while the 3rd prize winnings went to the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins.

For more information or to obtain an entry form and content criteria, please call 1-800-734-4131, or log on to www.LillyOncologyOnCanvas.com.

Recent Videos
Efficacy results from the MASAI trial preceded the creation of the UK-funded EDITH trial, assessing 5 AI platforms in 700,000 women undergoing mammography.
Combining sotorasib with panitumumab may reduce the burden of disease in patients with KRAS G12C-mutated metastatic colorectal cancer.
6 experts are featured in this series.
6 experts are featured in this series.
Findings from the phase 2b ReNeu trial show significant pain relief with mirdametinib in adult and pediatric patients with NF1-PN.
Findings from the CodeBreak 300 study have cemented sotorasib/panitumumab as a third-line treatment option for KRAS G12C-mutated colorectal cancer.
The dispersible tablet formulation of mirdametinib may offer convenience to patients with NF1-PN and difficulty with swallowing pills.
Related Content